Lufotrelvir

DB16514InvestigationalSmall molecule

PF-07304814 is a small molecule prodrug that targets the 3CLpro protease (Mpro), which is used by viruses like SARS-CoV-2 to assemble and multiply . Once administered through intravenous infusion, the... Once administered through intravenous infusion, the compound is cleaved into PF-00835231 to exert its anti-viral effects.

Mechanism: The structure of PF-07304814 contains a phosphate group, allowing the compound to be soluble and then subsequently cleaved in tissue by alkaline phosphatase. This step allows for the release of PF-00835231, which is the compound that exerts anti-viral activity against the 3CL protease of SARS-CoV-2. The active compound, PF-00835231, was shown to have potent and broad-spectrum inhibitory activity against numerous coronavirus 3CL proteases.
Curator reviewed · 3 references
Formula / weight: C₂₄H₃₃N₄O₉P · 552.521 g/mol (avg)
Code names: PF-07304814

Resolves to

Compound

UNIIXJ51YOB1SC

Structure

InChIKeyFQKALOFOWPDTED-WBAXXEDZSA-NSMILES[H][C@@]1(C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)C2=CC3=C(N2)C=CC=C3OC)C(=O)COP(O)(O)=O)CCNC1=O

Targets

P0DTD1rep

What you can answer from here — as of October 27, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lufotrelvir, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account